Relevant bibliographies by topics / Pharmacological ablation

Academic literature on the topic 'Pharmacological ablation'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacological ablation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmacological ablation"

1

Gourraud, Jean-Baptiste, Jason G. Andrade, Laurent Macle, and Blandine Mondésert. "Pharmacological Tests in Atrial Fibrillation Ablation." Arrhythmia & Electrophysiology Review 5, no. 3 (2016): 170. http://dx.doi.org/10.15420/aer.2016:27:2.

Full text
Abstract:
The invasive management of atrial fibrillation (AF) has been considerably changed by the identification of major sites of AF initiation and/or maintenance within the pulmonary vein antra. Percutaneous catheter ablation of these targets has become the standard of care for sustained maintenance of sinus rhythm. Long-term failure of ablation is related to an inability to create a durable transmural lesion or to identify all of the non-pulmonary vein arrhythmia triggers. Pharmacological challenges during catheter ablation have been suggested to improve outcomes in both paroxysmal and persistent AF. Herein we review the mechanism and evidence for the use of pharmacological adjuncts during the catheter ablation of AF.
APA, Harvard, Vancouver, ISO, and other styles
2

Rordorf, Roberto, Simone Savastano, Edoardo Gandolfi, Alessandro Vicentini, Barbara Petracci, and Maurizio Landolina. "Pharmacological therapy following catheter ablation of atrial fibrillation." Journal of Cardiovascular Medicine 13, no. 1 (January 2012): 9–15. http://dx.doi.org/10.2459/jcm.0b013e32834d5880.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Baher, Alex, and Nassir F. Marrouche. "Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?" Arrhythmia & Electrophysiology Review 7, no. 2 (2018): 91. http://dx.doi.org/10.15420/aer.2018.17.2.

Full text
Abstract:
AF in patients with heart failure and reduced ejection fraction (HFrEF) is common and is associated with an increased risk of stroke, heart failure hospitalisation and all-cause mortality. Rhythm control of AF in this population has been traditionally limited to the use of antiarrhythmic drugs. Clinical trials assessing superiority of pharmacological rhythm control over rate control have been largely disappointing. Catheter ablation has emerged as a viable alternative to pharmacological rhythm control in symptomatic AF and has enjoyed significant technological advancements over the past decade. Recent clinical trials have suggested that catheter ablation is superior to pharmacological interventions in patients with co-existing AF and HFrEF. In this article, we will review the therapeutic options for AF in patients with HFrEF in the context of the latest clinical trials beyond the current established guidelines.
APA, Harvard, Vancouver, ISO, and other styles
4

Hung, Yuan, Shih-Ann Chen, Shih-Lin Chang, Wei-Shiang Lin, and Wen-Yu Lin. "Atrial Tachycardias After Atrial Fibrillation Ablation: How to Manage?" Arrhythmia & Electrophysiology Review 9, no. 2 (August 13, 2020): 54–60. http://dx.doi.org/10.15420/aer.2020.07.

Full text
Abstract:
With catheter ablation becoming effective for non-pharmacological management of AF, many cases of atrial tachycardia (AT) after AF ablation have been reported in the past decade. These arrhythmias are often symptomatic and respond poorly to medical therapy. Post-AF-ablation ATs can be classified into the following three categories: focal, macroreentrant and microreentrant ATs. Mapping these ATs is challenging because of atrial remodelling and its complex mechanisms, such as double ATs and multiple-loop ATs. High-density mapping can achieve precise identification of the circuits and critical isthmuses of ATs and improve the efficacy of catheter ablation. The purpose of this article is to review the mechanisms, mapping and ablation strategy, and outcome of ATs after AF ablation.
APA, Harvard, Vancouver, ISO, and other styles
5

Piotrowski, Roman, and Piotr Kułakowski. "Ablation in persistent atrial fibrillation." In a good rythm 3, no. 48 (October 26, 2018): 17–23. http://dx.doi.org/10.5604/01.3001.0012.7127.

Full text
Abstract:
Atrial fibrillation is an arrhythmia which causes deterioration of the quality of life and increases frequency of hospitalizations. It also causes a significant increase in the risk of stroke, heart failure and other thrombo-embolic complications. Ablation is more effective than pharmacological treatment in patients with paroxysmal atrial fibrillation, however data and recommendations in patients with persistent atrial fibrillation are less clear. This article summarizes the issues that should be considered in planning ablation of persistent atrial fibrillation in order to optimize efficacy of this treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

He, Bo, Benjamin J. Scherlag, Hiroshi Nakagawa, Ralph Lazzara, and Sunny S. Po. "The Intrinsic Autonomic Nervous System in Atrial Fibrillation: A Review." ISRN Cardiology 2012 (June 19, 2012): 1–8. http://dx.doi.org/10.5402/2012/490674.

Full text
Abstract:
The procedure of catheter ablation for the treatment of drug resistant atrial fibrillation (AF) has evolved but still relies on lesion sets intended to isolate areas of focal firing, mainly the myocardial sleeves of the pulmonary veins (PVs), from the rest of the atria. However the success rates for this procedure have varied inversely with the type of AF. At best success rates have been 20 to 30% below that of other catheter ablation procedures for Wolff-Parkinson-White syndrome, atrioventricular junctional re-entrant tachycardia and atrial flutter. Basic and clinical evidence has emerged suggesting a critical role of the ganglionated plexi (GP) at the PV-atrial junctions in the initiation and maintenance of the focal form of AF. At present the highest success rates have been obtained with the combination of PV isolation and GP ablation both as catheter ablation or minimally invasive surgical procedures. Various lines of evidence from earlier and more recent reports provide that both neurally based and myocardially based forms of AF can separately dominate or coexist within the context of atrial remodeling. Future studies are focusing on non-pharmacological, non-ablative approaches for the prevention and treatment of AF in order to avoid the substantive complications of both these regimens.
APA, Harvard, Vancouver, ISO, and other styles
7

Eysenck, William, and Magdi Saba. "Rhythm Control in Heart Failure Patients with Atrial Fibrillation." Arrhythmia & Electrophysiology Review 9, no. 3 (November 5, 2020): 161–66. http://dx.doi.org/10.15420/aer.2020.23.

Full text
Abstract:
AF and heart failure (HF) commonly coexist. Left atrial ablation is an effective treatment to maintain sinus rhythm (SR) in patients with AF. Recent evidence suggests that the use of ablation for AF in patients with HF is associated with an improved left ventricular ejection fraction and lower death and HF hospitalisation rates. We performed a systematic search of world literature to analyse the association in more detail and to assess the utility of AF ablation as a non-pharmacological tool in the treatment of patients with concomitant HF.
APA, Harvard, Vancouver, ISO, and other styles
8

Mukherjee, Rahul K., Steven E. Williams, and Mark D. O’Neill. "Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All." Arrhythmia & Electrophysiology Review 7, no. 2 (2018): 84. http://dx.doi.org/10.15420/aer.2018.11.3.

Full text
Abstract:
Atrial fibrillation (AF) is common in patients with heart failure and is associated with poorer clinical outcomes compared with patients with heart failure alone. Recent evidence has challenged previous treatment paradigms in which rate control was considered equivalent to rhythm control in this population. Catheter ablation has emerged as a safe and effective treatment strategy in selected patients and overcomes the issues of limited efficacy and drug toxicities associated with pharmacological rhythm control. Numerous studies have explored the benefits of catheter ablation in patients with heart failure, but these have included heterogeneous patient cohorts and variable ablation strategies. This state-of-the-art review explores the evidence from these trials and examines the need for tailored, patient-specific strategies for AF ablation in patients with heart failure.
APA, Harvard, Vancouver, ISO, and other styles
9

Joll, J. Ethan, Cynthia R. Clark, Christine S. Peters, Michael A. Raddatz, Matthew R. Bersi, and W. David Merryman. "Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model." PLOS ONE 15, no. 11 (November 25, 2020): e0238407. http://dx.doi.org/10.1371/journal.pone.0238407.

Full text
Abstract:
Calcific aortic valve disease (CAVD) is a deadly disease that is rising in prevalence due to population aging. While the disease is complex and poorly understood, one well-documented driver of valvulopathy is serotonin agonism. Both serotonin overexpression, as seen with carcinoid tumors and drug-related agonism, such as with Fenfluramine use, are linked with various diseases of the valves. Thus, the objective of this study was to determine if genetic ablation or pharmacological antagonism of the 5-HT2B serotonin receptor (gene: Htr2b) could improve the hemodynamic and histological progression of calcific aortic valve disease. Htr2b mutant mice were crossed with Notch1+/- mice, an established small animal model of CAVD, to determine if genetic ablation affects CAVD progression. To assess the effect of pharmacological inhibition on CAVD progression, Notch1+/- mice were treated with the 5-HT2B receptor antagonist SB204741. Mice were analyzed using echocardiography, histology, immunofluorescence, and real-time quantitative polymerase chain reaction. Htr2b mutant mice showed lower aortic valve peak velocity and mean pressure gradient–classical hemodynamic indicators of aortic valve stenosis–without concurrent left ventricle change. 5-HT2B receptor antagonism, however, did not affect hemodynamic progression. Leaflet thickness, collagen density, and CAVD-associated transcriptional markers were not significantly different in any group. This study reveals that genetic ablation of Htr2b attenuates hemodynamic development of CAVD in the Notch1+/- mice, but pharmacological antagonism may require high doses or long-term treatment to slow progression.
APA, Harvard, Vancouver, ISO, and other styles
10

Dan, Gheorghe-Andrei. "Rhythm Control in AF: Have We Reached the Last Frontier?" European Cardiology Review 14, no. 2 (July 11, 2019): 77–81. http://dx.doi.org/10.15420/ecr.2019.8.1.

Full text
Abstract:
AF is a worldwide epidemic, affecting approximately 33 million people, and its rising prevalence is expected to account for increasing clinical and public health costs. AF is associated with an increased risk of MI, heart failure, stroke, dementia, chronic kidney disease and mortality. Preserving sinus rhythm is essential for a better outcome. However, because of the inherent limits of both pharmacological and interventional methods, rhythm strategy management is reserved for symptom and quality-of-life improvement. While ‘classical’ antiarrhythmic drug therapy remains the first-line therapy for rhythm control, its efficacy and safety are limited by empirical use, proarrhythmic risk and organ toxicity. Ablative techniques have had an impressive development, but AF ablation still failed to demonstrate a significant impact on hard endpoints. Understanding of the complex mechanisms of AF will help to develop new vulnerable targets to therapy. Promising molecules are under development, intended to fill the gap between the current pharmacological treatment aimed at maintaining sinus rhythm and the expectations from rhythm strategy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmacological ablation"

1

Baratti, Greta. "ENVIRONMENTAL GEOMETRY IN FISHES AND TORTOISES: EFFECT OF LANDMARKS, BEHAVIOURAL METHODOLOGIES, AND SENSORY CHANNELS ON SPATIAL REORIENTATION." Doctoral thesis, Università degli studi di Trento, 2022. https://hdl.handle.net/11572/356341.

Full text
Abstract:
The present Thesis explored spatial reorientation behaviour of three species of fish (the zebrafish Danio rerio, the redtail splitfin fish Xenotoca eiseni, the goldfish Carassius auratus) and one species of reptiles (the Hermann tortoise Testudo hermanni) to widely assess three issues: 1) the use of environmental geometry with and without landmarks; 2) the role of two geometric tasks, one driven by spontaneous behaviour (“social-cued memory task”) and the other by learning processes (“rewarded exit task”); 3) the involvement of extra-visual sensory channels in visual transparency conditions, and motion patterns. The present Thesis applied behavioural assessments and analyses to pursue a line of comparison, across species, methodologies, and sensory systems. As regards environmental geometry and landmarks in fish and tortoises (Chapter 2), the studies were carried out within several apparatuses, that is, a rectangular opaque arena or two different sized square opaque arenas or a transparent square arena, with conspicuous or local landmarks: Study 1, Conspicuous landmark (blue wall) in zebrafish; Study 2: Local landmarks (corner panels) in zebrafish; Study 3, Environmental geometry in tortoises; Study 4, Conspicuous landmark (blue wall) in tortoises. As regards spontaneous vs. acquired geometric spatial reorientation in fishes (Chapter 3), the studies were carried out within a rectangular or square transparent arena, with or without geometric cues or a 3D landmark: Study 5, Nonvisual environmental geometry in zebrafish, redtail splitfin fish, and goldfish; Study 6, Isolated environmental geometric cues in zebrafish; Study 7, 3D outside landmark (blue cylinder) in zebrafish. As regards extra-visual sensory systems and motion patterns in fish (Chapter 4), one study was carried out within a rectangular transparent arena: Study 8, Lateral line pharmacological ablation in zebrafish. In respect of comparisons among species, overall results suggested that zebrafish, redtail splitfin fish, and goldfish reoriented similarly through transparent surfaces, which defined a distinctive global shape, supporting spatial reorientation under undefined situations (e.g., seek out food within a visually lacking and unenriched environment) as a shared skill among teleosts, despite ecological specificities. Likewise, the Hermann tortoise reoriented within a geometric environment with precision to meet a survival need, suggesting that even non-nomadic species that hibernate for long can benefit from orientation by extended terrain surfaces. In respect of memory tests (“working” vs. “reference”, spontaneous vs. acquired), overall results indicated that the rewarded exit task designed to train fish and tortoise to reorient required learning processes allowing them to overcome natural predispositions to improve other related abilities, such as landmark-use. The dissociation between working and reference memory in spatial domain must be considered highly dependent on task’s demands where attentional factors determine short-term memories and motivational states long-term ones. In respect of sensory channels and motion patterns, overall results revealed that fish and tortoises used modalities driven by touch, in synch with sight, to determine geometric parameters during spatial reorientation. Therefore, a promising link between other vertebrates and humans takes place, in consideration of orientation mechanisms used to face situations of visual deprivation or impairments. The present Thesis may even contribute to a general understanding of reorientation behaviour in phylogenetically remote vertebrate species, thus supporting the widespread use of geometry-grounded tools in everyday activities. This also provides comparative support among species that inhabit on Earth and share cognitive adaptations to deal with similar requests.
APA, Harvard, Vancouver, ISO, and other styles
2

Fox, Deborah Ann. "Effects of ablation of the myenteric plexus on the pharmacological responses and electrical activity of rat jejunal muscle." 1985. http://catalog.hathitrust.org/api/volumes/oclc/13211651.html.

Full text
Abstract:
Thesis (Ph. D.)--University of Wisconsin--Madison, 1985.
Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Pharmacological ablation"

1

Glannon, Walter. Psychiatric Neuroethics I. Edited by John Z. Sadler, K. W. M. Fulford, and Werdie (C W. ). van Staden. Oxford University Press, 2014. http://dx.doi.org/10.1093/oxfordhb/9780198732372.013.30.

Full text
Abstract:
Severe psychiatric disorders may be resistant to conventional pharmacological and psychotherapeutic treatments. Invasive interventions such as deep-brain stimulation (DBS) and neurosurgical ablation (lesioning) can modulate dysfunctional neural circuits implicated in these disorders. Yet these two forms of psychiatric neurosurgery are still experimental and investigational and thus their safety and efficacy have yet to be established. This chapter is an examination and discussion of the main ethical issues surrounding the experimental use of DBS and lesioning for treatment-refractory psychiatric disorders. I address questions regarding research subjects’ exposure to risk and informed consent to be enrolled in clinical trials testing these techniques for major depression and obsessive-compulsive disorder. These questions include whether or to what extent the therapeutic misconception influences decisions to enroll in these trials. I then explore similar questions about the use of DBS for schizophrenia and anorexia nervosa. Finally, I discuss the obligations of researchers conducting these studies to research subjects.
APA, Harvard, Vancouver, ISO, and other styles
2

Elliott, Perry, and Alexandros Protonotarios. Arrhythmogenic right ventricular cardiomyopathy: management of symptoms and prevention of sudden cardiac death. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0361.

Full text
Abstract:
Patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) have arrhythmia-related symptoms or are identified during screening of an affected family. Heart failure symptoms occur late in the disease’s natural history. As strenuous exercise has been associated with disease acceleration and worsening of ventricular arrhythmias, lifestyle modification with restricted athletic activities is recommended upon disease diagnosis or even identification of mutation carrier status. An episode of an haemodynamically unstable, sustained ventricular tachycardia or ventricular fibrillation as well as severe systolic ventricular dysfunction constitute definitive indications for implantable cardioverter defibrillator (ICD) implantation, which should also be considered following tolerated sustained or non-sustained ventricular tachycardia episodes, syncope, or in the presence of moderate ventricular dysfunction. Antiarrhythmic medications are used as an adjunct to device therapy. Catheter ablation is recommended for incessant ventricular tachycardia or frequent appropriate ICD interventions despite maximal pharmacological therapy. Amiodarone alone or in combination with beta blockers is most effective for symptomatic ventricular arrhythmias. Beta blockers are considered for use in all patients with a definite diagnosis but evidence for their prognostic benefit is sparse. Heart failure symptoms are managed using standard protocols and heart transplantation is considered for severe ventricular dysfunction or much less commonly uncontrollable ventricular arrhythmias.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pharmacological ablation"

1

Brignole, Michele, Lorella Gianfranchi, Carlo Menozzi, Paolo Alboni, Giacomo Musso, Maria Grazia Bongiorni, Maurizio Gasparini, et al. "Severe Paroxysmal Atrial Fibrillation: Atrioventricular Junction Ablation and DDDR Mode-Switching Pacemaker Versus Pharmacological Treatment." In Developments in Cardiovascular Medicine, 29–34. Dordrecht: Springer Netherlands, 1998. http://dx.doi.org/10.1007/978-94-011-5254-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kaushik, Nayanjyoti, James Arter Chapman, Andrew Gillaspie, Stephen Ackerman, Peter Gallagher, Deobrat Mallick, and Steven J. Bailin. "Recent Advances in Catheter Ablation for Atrial Fibrillation and Non-pharmacological Stroke Prevention." In Atrial Fibrillation - Diagnosis and Management in the 21st Century [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106319.

Full text
Abstract:
Atrial Fibrillation is a common arrhythmia affecting 6 million people in the United States and 33 million people worldwide, associated with significant morbidity. Whereas restoration and maintenance of sinus rhythm can translate into clinical benefit, early intervention in course of the disease can influence success and efficacy of intervention has been speculative and uncertain over past decade despite several literature and scientific studies. During past three decades catheter and surgical ablation of AF have evolved from an investigational status to a widely offerred definitive treatment now. With recent advances in mapping technology, ablation energy delivery, better understanding of pathogenesis and mechanism of AF there has been a paradigm shift in clinical decision making, patient selection, patient-physician discussion about various rhythm control strategy due to an ever improving safety and efficacy of the procedure. In this chapter we will briefly review the landmark clinical trials that has changed the outlook towards rhythm control strategy beginning from early trials such as AFFIRM, telling us rhythm control was no better than rate control to recent studies and EAST AFNET, which showed benefits of rhythm control. We will discuss differences in ablation strategy, safety and efficacy between paroxysmal AF vs. Persistent/Longstanding Persistent AF from a trigger and substrate view and pulmonary vein and non pulmonary vein targets for ablation. We will also elaborate on different energy sources for ablation such as Radiofrequency (RF), Cryoablation, newer ablation techniques such as Vein of Marshall alcohol ablation, High Power short duration ablation, Pulsed Field Ablation, Surgical ablation and Hybrid Convergent Ablation etc. Since this chapter is mostly intended towards diagnosis and management of AF in twenty-first century, authors have restricted mainly to recent developments only and purposefully have not expanded on already established preexisting knowledge about topics such as pharmacological rhythm control, rate control, Atrio-Ventricular node ablation with pacemaker implantation, direct current cardio version etc. In conclusion, with recent emerging evidence, importance of rhythm control is being increasingly recognized. Catheter ablation is more commonly performed with improving safety and efficacy. There are newer technology and ablation strategy available and should be offered to patient while discussing a comprehensive management of AF with careful review of risk benefit analysis.
APA, Harvard, Vancouver, ISO, and other styles
3

Dangas, George, and Edwin Lee. "Pharmacological use of ethanol for myocardial septal ablation." In Textbook of Interventional Cardiovascular Pharmacology, 603–12. CRC Press, 2007. http://dx.doi.org/10.3109/9780203463048-53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nogami, Akihiko. "Bundle branch reentry tachycardia." In ESC CardioMed, edited by Brian Olshansky, 2270–75. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0537.

Full text
Abstract:
Bundle branch reentry ventricular tachycardia, a unique form of reentrant ventricular tachycardia involving the His–Purkinje system, occurs in patients with cardiomyopathy and His–Purkinje conduction disease. It responds poorly to pharmacological therapy and can be cured effectively with catheter ablation. However, even after ablation, patients may remain at risk for total mortality and sudden cardiac death and may require further therapies including cardiac resynchronization therapy defibrillators.
APA, Harvard, Vancouver, ISO, and other styles
5

Kulenthiran, Saarraaken, Sebastian Ewen, and Felix Mahfoud. "Device-based treatment for hypertension." In ESC CardioMed, edited by Bryan Williams, 2458–65. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0570.

Full text
Abstract:
Autonomic imbalance is thought to play an important role in the pathophysiology of hypertension. Despite the availability of diverse pharmacological options, non-adherence to medication or inability to tolerate current pharmacological therapies has led to the development of various device-based therapy options. Inhibiting components of the sympathetic nervous system offers a unique opportunity to target the ‘neural’ component of the neurohormonal axis. Combining novel drug-, device-, and procedure-based strategies with improved utilization of existing therapies (including appropriate attention to diet, exercise, and weight control) may result in improved outcomes. This chapter discusses the rationale and current experimental and clinical data of several novel device-based treatment options—renal nerve ablation, carotid body ablation, carotid baroreceptor stimulation, and central arteriovenous anastomosis.
APA, Harvard, Vancouver, ISO, and other styles
6

Kulenthiran, Saarraaken, Sebastian Ewen, and Felix Mahfoud. "Device-based treatment for hypertension." In ESC CardioMed, edited by Bryan Williams, 2458–65. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0570_update_001.

Full text
Abstract:
Autonomic imbalance is thought to play an important role in the pathophysiology of hypertension. Despite the availability of diverse pharmacological options, non-adherence to medication or inability to tolerate current pharmacological therapies has led to the development of various device-based therapy options. Inhibiting components of the sympathetic nervous system offers a unique opportunity to target the ‘neural’ component of the neurohormonal axis. Combining novel drug-, device-, and procedure-based strategies with improved utilization of existing therapies (including appropriate attention to diet, exercise, and weight control) may result in improved outcomes. This chapter discusses the rationale and current experimental and clinical data of several novel device-based treatment options—renal nerve ablation, carotid body ablation, carotid baroreceptor stimulation, and central arteriovenous anastomosis.
APA, Harvard, Vancouver, ISO, and other styles
7

Boriani, Giuseppe. "Health economy." In ESC CardioMed, 2107–8. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0493.

Full text
Abstract:
Management of supraventricular tachycardias (SVTs) through drugs or interventional procedures, such as catheter ablation, has the aim to reduce symptoms, morbidity, and, possibly, mortality related to arrhythmic events. As shown in cost-of-illness studies, many arrhythmic conditions, including SVT, induce use of resources and substantial costs to the healthcare system. With regard to the costs of radiofrequency catheter ablation procedures, variable data have been reported in the literature (from $5000 to $16,000), varying not only according to setting and country but also according to consideration of actual costs or billed hospital charges. A series of studies evaluated the cost-effectiveness of ablation versus pharmacological treatment of SVTs in different settings and showed a favourable cost-effectiveness profile for ablation therapy in SVT patients with frequent arrhythmia recurrences. In patients with symptoms that can be controlled with medications, the upfront cost of ablation therapy is equalled, along with time, by the cumulative cost of medical therapy, usually after a time period of around 10 years. Currently the perspective of a curative treatment and patient preferences have expanded the indication to catheter ablation therapy in SVT out of the setting of drug refractory arrhythmic episodes and ablation is currently proposed as a first-line treatment option in SVT patients. Both European and American consensus documents and guidelines make recommendations based on this approach.
APA, Harvard, Vancouver, ISO, and other styles
8

Ommen, Steve R. "Hypertrophic cardiomyopathy: invasive management of left ventricular outflow tract obstruction." In ESC CardioMed, 1459–62. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0353.

Full text
Abstract:
Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy can result in considerable symptoms. While pharmacological therapies are the first-line treatment for most patients, there are invasive therapies that have shown excellent success in relieving these drug-refractory symptoms. Surgical septal myectomy and percutaneous alcohol septal ablation, each with relative merits and risks, offer high success rates when performed in the context of specialized hypertrophic cardiomyopathy programmes.
APA, Harvard, Vancouver, ISO, and other styles
9

Grandhe, Radhika, Eli Johnson Harris, and Eugene Koshkin. "Trigeminal Neuralgia." In Neuropathic Pain, edited by Radhika Grandhe, Eli Johnson Harris, and Eugene Koshkin, 257–66. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190298357.003.0030.

Full text
Abstract:
Trigeminal neuralgia is a rare neuropathic pain condition but can be very disabling. The hallmark is brief episodes of intense, radiating pain within the territory of trigeminal nerve distribution. It is typically unilateral, often accompanied by facial spasms and can be triggered by facial movements in a majority of patients. Microvascular compression of trigeminal ganglion is the etiology for most patients with classical trigeminal neuralgia. Some patients can have continuous facial pain in addition to paroxysms of pain. Trigeminal neuralgia is a clinical diagnosis, but MRI is done to rule out secondary causes or to detect microvascular compression. Pharmacological therapy with first-line agents—carbamazepine or oxcarbazepine—is the preferred treatment. Patients with failed pharmacological therapy are considered for surgical decompression, ablation procedures, or Gamma Knife surgery.
APA, Harvard, Vancouver, ISO, and other styles
10

Guarguagli, Silvia, and Sabine Ernst. "Atrial Tachycardia Including Atrial Flutter." In Manual of Cardiovascular Medicine, 221–28. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198850311.003.0027.

Full text
Abstract:
Atrial tachycardia (AT) is a regular atrial rhythm at a constant rate of >100 beats per minute originating outside of the sinus node. AT originates exclusively in the atrial substrate (without involving the conduction system) and results from abnormal impulse generation in the atria leading to focal or micro or macro re-entrant AT, the latter also called atrial flutter. Causes involve prior cardiac surgery, atrial remodelling due to heart failure, mitral or tricuspid regurgitation, or stenosis or hypertension. Furthermore, it may occur after catheter ablation, in cardiomyopathies, due to electrolyte imbalance (e.g. hypokalaemia), and due to alcohol, cocaine, and other stimulants. Atrial flutter may require synchronized cardioversion in those haemodynamically unstable or symptomatic despite medications. Alternatively, acute pharmacological cardioversion maybe considered. Catheter ablation is highly effective to prevent recurrences of atrial flutter. Anticoagulation may be considered.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmacological ablation"

1

Cufí, S., C. Oliveras-Ferraros, A. Vazquez-Martin, T. Sauri-Nadal, Barco S. Del, B. Martin-Castillo, E. Lopez-Bonet, and JA Menendez. "P1-12-14: Genetic Ablation or Pharmacological Inhibition of Autophagy Suppresses Intrinsic Resistance of Breast Cancer to HER2−Targeted Therapies." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p1-12-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmacological ablation' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography